U.S. Panel Splits On Abbott Laboratories Diet Drug Ban

(Reuters) - A U.S. advisory panel was divided over whether to recommend banning Abbott Laboratories' (ABT.N) controversial weight-loss drug on Wednesday, although most agreed that the drug's heart risk cast a shadow on its future use.